ASH 2014 | Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia
Eytan Stein
• 5 Dec 2014
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Eytan Stein (Memorial Sloan-Kettering Cancer Center, New York, NY) discusses a Phase I study of AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, in IDH2-mutant acute myeloid leukemia or pre-leukemia (including myelodysplastic syndromes, chronic myelomonocytic leukemia, and myeloproliferative neoplasms).
